Gossamer Bio (NASDAQ:GOSS) Upgraded to “Buy” at ValuEngine

ValuEngine upgraded shares of Gossamer Bio (NASDAQ:GOSS) from a hold rating to a buy rating in a report issued on Thursday morning, ValuEngine reports.

Separately, Zacks Investment Research lowered shares of Gossamer Bio from a buy rating to a hold rating in a research report on Wednesday, July 17th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Gossamer Bio has an average rating of Buy and a consensus price target of $28.00.

Shares of GOSS traded down $1.84 during mid-day trading on Thursday, reaching $18.57. 266,524 shares of the stock traded hands, compared to its average volume of 205,657. The business has a fifty day simple moving average of $20.80. The firm has a market cap of $1.22 billion and a P/E ratio of -0.82. The company has a current ratio of 19.79, a quick ratio of 19.79 and a debt-to-equity ratio of 0.02. Gossamer Bio has a 1 year low of $15.59 and a 1 year high of $25.06.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.27). Equities analysts anticipate that Gossamer Bio will post -2.61 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank bought a new stake in shares of Gossamer Bio during the 2nd quarter worth $816,000. BNP Paribas Arbitrage SA bought a new stake in Gossamer Bio in the second quarter worth $42,000. FMR LLC bought a new stake in Gossamer Bio in the first quarter worth $26,576,000. Redmile Group LLC bought a new stake in Gossamer Bio in the first quarter worth $5,418,000. Finally, Omega Fund Management LLC bought a new stake in Gossamer Bio in the first quarter worth $150,681,000. 52.76% of the stock is owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Recommended Story: Stock Split

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.